[
1. Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today. 2021;26(2):593-603.10.1016/j.drudis.2020.11.025769455633253920
]Search in Google Scholar
[
2. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021; 13(1):1860476.10.1080/19420862.2020.1860476783376133459118
]Search in Google Scholar
[
3. Aschenbrenner DS. Monoclonal antibodies receive EUA to treat mild to moderate COVID-19. Am J Nurs. 2021;121(2):26.10.1097/01.NAJ.0000734112.15618.f433497123
]Search in Google Scholar
[
4. Tulledge-Scheitel S, Bell SJ, Larsen JJ, Bierle DM, Takahashi P, Moehnke DE, et al. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. J Am Geriatr Soc. 2021;69(2):868-73.10.1111/jgs.17090801348633619724
]Search in Google Scholar
[
5. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51.10.1056/NEJMoa2035002778110233332778
]Search in Google Scholar
[
6. Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, et al. Initial guidance on use of monoclonal antibody therapy for treatment of COVID-19 in children and adolescents. J Pediatric Infect Dis Soc. 2021:10(5):629-34.10.1093/jpids/piab124890334935107571
]Search in Google Scholar
[
7. Conditions of use casirivimab and imdevimab (REGN-COV2). Annex I. Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorized product available for use. European Medicines Agency, 26 February 2021. (https://www.ema.europa.eu/en/documents/referral/regn-cov2-antibody-combination-casirivimab/imdevimabcovid-19-conditions-use-conditions-distribution-patients-targeted-conditions-safety_en.pdf) [accessed on 26 February 2021]
]Search in Google Scholar
[
8. Pallotta AM, Kim C, Gordon SM, Kim A. Monoclonal antibodies for treating COVID-19. Cleeve Clin J Med. 2021. [online ahead of print]10.3949/ccjm.88a.ccc07433597176
]Search in Google Scholar
[
9. Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850-4.10.1126/science.abf9302796321933495308
]Search in Google Scholar
[
10. Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020;4:1134-9.10.1038/s41551-020-00660-2789185833293725
]Search in Google Scholar
[
11. Deb P, Molla MMA, Rahman KMS. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87-91.10.1016/j.bsheal.2021.02.001787284933585808
]Search in Google Scholar
[
12. Sun Y, Ho M. Emerging antibody-based therapeutics against SARSCoV-2 during the global pandemic. Antib Ther. 2020;3(4):246-256.
]Search in Google Scholar
[
13. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARSCoV-2 antibody cocktail. Science. 2020;369:1010-4.10.1126/science.abd0827729928432540901
]Search in Google Scholar
[
14. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110-5.10.1126/science.abe2402785739633037066
]Search in Google Scholar
[
15. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369(6506):1014-8.10.1126/science.abd0831729928332540904
]Search in Google Scholar
, 